OBJECTIVE: The objective was to determine the maximum tolerated dose and the dose-limiting toxicity of panobinostat (LBH589) when administered as a single agent to adult patients with advanced solid tumors or cutaneous T-cell lymphoma whose disease had progressed despite standard therapy or for whom no standard therapy existed. METHODS: Panobinostat was administered orally once daily on Monday, Wednesday, and Friday of each week. A total of 13 patients were treated with one of three initial doses: 10 mg (n = 3), 15 mg (n = 4), or 20 mg (n = 6). RESULTS: No dose-limiting toxicity was observed in 12 evaluable patients. The most frequently reported adverse events, regardless of whether they were related to the study drug, were diarrhea and nausea in 10 patients (76.9%). Thrombocytopenia was reported in 12 of 13 patients (92.3%). Five of 11 patients (45.4%) had stable disease. CONCLUSION: Panobinostat administered orally once daily on Monday, Wednesday, and Friday of each week was well tolerated at doses up to 20 mg in Japanese patients. Dose escalation did not proceed after exploration of the 20 mg dose due to emerging global clinical data at that time.
OBJECTIVE: The objective was to determine the maximum tolerated dose and the dose-limiting toxicity of panobinostat (LBH589) when administered as a single agent to adult patients with advanced solid tumors or cutaneous T-cell lymphoma whose disease had progressed despite standard therapy or for whom no standard therapy existed. METHODS:Panobinostat was administered orally once daily on Monday, Wednesday, and Friday of each week. A total of 13 patients were treated with one of three initial doses: 10 mg (n = 3), 15 mg (n = 4), or 20 mg (n = 6). RESULTS: No dose-limiting toxicity was observed in 12 evaluable patients. The most frequently reported adverse events, regardless of whether they were related to the study drug, were diarrhea and nausea in 10 patients (76.9%). Thrombocytopenia was reported in 12 of 13 patients (92.3%). Five of 11 patients (45.4%) had stable disease. CONCLUSION:Panobinostat administered orally once daily on Monday, Wednesday, and Friday of each week was well tolerated at doses up to 20 mg in Japanese patients. Dose escalation did not proceed after exploration of the 20 mg dose due to emerging global clinical data at that time.
Authors: Owen A O'Connor; Mark L Heaney; Lawrence Schwartz; Stacie Richardson; Robert Willim; Barbara MacGregor-Cortelli; Tracey Curly; Craig Moskowitz; Carol Portlock; Steven Horwitz; Andrew D Zelenetz; Stanley Frankel; Victoria Richon; Paul Marks; William K Kelly Journal: J Clin Oncol Date: 2005-12-05 Impact factor: 44.544
Authors: M Duvic; K Hymes; P Heald; D Breneman; A G Martin; P Myskowski; C Crowley; R C Yocum Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: Leigh Ellis; Yan Pan; Gordon K Smyth; Daniel J George; Chris McCormack; Roxanne Williams-Truax; Monica Mita; Joachim Beck; Howard Burris; Gail Ryan; Peter Atadja; Dale Butterfoss; Margaret Dugan; Kenneth Culver; Ricky W Johnstone; H Miles Prince Journal: Clin Cancer Res Date: 2008-07-15 Impact factor: 12.531
Authors: Aaron N Chang; Alan B Cantor; Yuko Fujiwara; Maya B Lodish; Steven Droho; John D Crispino; Stuart H Orkin Journal: Proc Natl Acad Sci U S A Date: 2002-06-20 Impact factor: 11.205
Authors: John H Strickler; Alexander N Starodub; Jingquan Jia; Kellen L Meadows; Andrew B Nixon; Andrew Dellinger; Michael A Morse; Hope E Uronis; P Kelly Marcom; S Yousuf Zafar; Sherri T Haley; Herbert I Hurwitz Journal: Cancer Chemother Pharmacol Date: 2012-06-29 Impact factor: 3.333
Authors: Chunzhang Yang; Cody L Swallows; Chao Zhang; Jie Lu; Hongbin Xiao; Roscoe O Brady; Zhengping Zhuang Journal: Proc Natl Acad Sci U S A Date: 2013-12-18 Impact factor: 11.205
Authors: Seth E Karol; Todd M Cooper; Paul E Mead; Kristine R Crews; John C Panetta; Thomas B Alexander; Jeffrey W Taub; Norman J Lacayo; Kenneth M Heym; Dennis J Kuo; Deborah E Schiff; Deepa Bhojwani; Yubin Ge; Jeffery M Klco; Raul C Ribeiro; Hiroto Inaba; Ching-Hon Pui; Jeffrey E Rubnitz Journal: Cancer Date: 2020-08-18 Impact factor: 6.860
Authors: Chandra R Tate; Lyndsay V Rhodes; H Chris Segar; Jennifer L Driver; F Nell Pounder; Matthew E Burow; Bridgette M Collins-Burow Journal: Breast Cancer Res Date: 2012-05-21 Impact factor: 6.466